Affinage

SPTBN1

Spectrin beta chain, non-erythrocytic 1 · UniProt Q01082

Length
2364 aa
Mass
274.6 kDa
Annotated
2026-06-10
38 papers in source corpus 17 papers cited in narrative 17 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SPTBN1 (βII-spectrin) is a multifunctional cytoskeletal adapter that integrates membrane-cytoskeletal architecture with the control of multiple signaling pathways, predominantly acting as a tumor and inflammation suppressor across hepatic, ovarian, renal, breast, and synovial tissues (PMID:25307947, PMID:33754058, PMID:32516133). As a scaffold for TGF-β signaling it is required for Smad3/Smad4 complex formation, and its loss derepresses Wnt/β-catenin and STAT3 transcriptional programs in hepatocellular carcinoma (PMID:25307947, PMID:25096061). A recurrent theme is restraint of NF-κB and JAK/STAT signaling: SPTBN1 stabilizes SOCS1 (an E3 ligase that degrades p65) and upregulates SOCS3, and it physically restricts p65 nuclear localization, so that its loss elevates p65, pro-inflammatory cytokines, miR-21, and CXCL1-driven M2 macrophage polarization (PMID:33754058, PMID:32516133, PMID:34358482, PMID:37921259); it also promotes METTL14-mediated m6A methylation of TRIM37 mRNA to dampen TRAF2/NF-κB-driven oxidative stress (PMID:40836352). SPTBN1 acts as a cytoplasmic anchor that sequesters PTTG1 (securin) to block its oncogenic nuclear translocation, and binds PIK3R2 to suppress PI3K/AKT signaling (PMID:38069214, PMID:36444616). Beyond signaling scaffolding, SPTBN1 functions as an RNA-binding protein controlling GPT2 mRNA stability and glycolytic metabolism, and its long isoform binds CDK1 to block the G2/M transition, with isoform choice governed by IGF2BP3/NUDT21-directed alternative polyadenylation (PMID:36527113, PMID:40301554). In the membrane-cytoskeletal domain, SPTBN1 maintains osteocyte plasma membrane integrity during mechanical loading to enable bone adaptation (PMID:39276238), and is exploited as a host factor that binds HIV-1 Gag to support viral infection in macrophages (PMID:23460728). Chromosomal fusion of SPTBN1 to receptor kinases such as FLT3 produces constitutively active, transforming oncoproteins (PMID:17764812).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 2007 Medium

    Established that SPTBN1 genomic rearrangement can drive transformation, showing the locus contributes oncogenic potential when fused to a kinase rather than only acting as a passive scaffold.

    Evidence RT-PCR fusion identification and Ba/F3 transformation assay with TKI dose-response for the SPTBN1-FLT3 fusion

    PMID:17764812

    Open questions at the time
    • Does not define the contribution of the SPTBN1 portion to fusion activity
    • Limited to a cell-line transformation model without patient outcome data
  2. 2012 Medium

    Identified a direct SPTBN1 protein partner (α-synuclein) and a cytoskeletal/neurite-outgrowth function, framing SPTBN1 as a binding hub whose activity is modulated by interacting proteins.

    Evidence Phage display, GST pull-down, Co-IP, colocalization, and neurite branching assay in SH-SY5Y cells

    PMID:22771809

    Open questions at the time
    • Binding domain not mapped
    • Physiological relevance to neuronal cytoskeleton in vivo not established
  3. 2013 High

    Revealed an unexpected pro-viral host role, showing SPTBN1 is required for HIV-1 infection of macrophages and is the target through which IL-27 confers resistance.

    Evidence Reciprocal siRNA knockdown/overexpression, Co-IP of SPTBN1 with HIV-1 Gag, and IL-27/TAK-1-MAPK pathway placement

    PMID:23460728

    Open questions at the time
    • Structural basis of the Gag interaction unresolved
    • Step of the viral life cycle requiring SPTBN1 not pinpointed
  4. 2014 Medium

    Connected SPTBN1 loss to derepression of STAT3 transcription, expanding its TGF-β scaffolding role into transcriptional control of an oncogenic effector.

    Evidence siRNA knockdown, STAT3 promoter luciferase reporter, ChIP-qPCR for ATF3/CREB2, and SPTBN1+/- mouse livers

    PMID:25096061

    Open questions at the time
    • Mechanism by which SPTBN1 controls ATF3/CREB2 occupancy not direct
    • Single-lab finding
  5. 2015 Medium

    Defined SPTBN1 as an adapter required for Smad3/Smad4 complex formation whose loss activates Wnt signaling, anchoring its tumor-suppressive role in TGF-β signal transduction.

    Evidence siRNA knockdown in HCC lines with kallistatin restoration rescue, Western blot, and xenograft assay

    PMID:25307947

    Open questions at the time
    • Direct physical scaffolding of Smad3/Smad4 not reconstituted here
    • Kallistatin regulation mechanism indirect
  6. 2020 Medium

    Generalized the SPTBN1–STAT pathway link to ovarian cancer via SOCS3, showing SPTBN1 suppresses JAK2/STAT3-driven EMT and proliferation.

    Evidence siRNA knockdown in EOC lines, SOCS3 overexpression and JAK2 inhibitor rescue, Sptbn1 KO MEFs, and xenograft

    PMID:32516133

    Open questions at the time
    • How SPTBN1 upregulates SOCS3 not defined
    • Single-lab finding
  7. 2021 High

    Mechanistically resolved SPTBN1 control of NF-κB by showing it stabilizes the p65 E3 ligase SOCS1, establishing a defined post-translational route to inflammatory suppression.

    Evidence IP-Western, reporter, ChIP-qPCR, EMSA, ELISA in HCC cells with SOCS1 rescue and Sptbn1+/- mice

    PMID:33754058

    Open questions at the time
    • Direct SPTBN1-SOCS1 interaction versus indirect regulation not fully distinguished
  8. 2021 High

    Identified a CASPASE-3-dependent SPTBN1 cleavage product that partners cleaved SREBP1 to drive lipogenesis, linking SPTBN1 to metabolic disease and liver cancer.

    Evidence Hepatocyte-specific SPTBN1 KO mice, Co-IP of SPTBN1/SREBP1 cleavage products, siRNA therapy, and human NASH tissue

    PMID:34910547

    Open questions at the time
    • Cleavage-product interaction interface not mapped
    • Trigger for CASPASE-3 cleavage of SPTBN1 not defined
  9. 2021 Medium

    Showed SPTBN1 promotes SETD7-mediated YAP methylation and degradation, coupling SPTBN1 to YAP-dependent autophagy in hepatic cells.

    Evidence Sptbn1+/- mice with DDC, rapamycin autophagy assay, YAP inhibition rescue, Western blot

    PMID:34737104

    Open questions at the time
    • SETD7-mediated methylation inferred rather than reconstituted
    • Direct SPTBN1-SETD7 interaction not shown
  10. 2021 Medium

    Extended the SPTBN1/p65 axis to breast cancer, linking SPTBN1 loss to p65-dependent transcription of oncogenic miR-21.

    Evidence siRNA knockdown, ChIP-qPCR, immunofluorescence, and xenograft

    PMID:34358482

    Open questions at the time
    • Whether SPTBN1 directly controls p65 nuclear translocation here versus via SOCS1 not separated
  11. 2022 Medium

    Uncovered an RNA-binding function for SPTBN1, showing it regulates GPT2 mRNA stability to restrain glycolysis in renal carcinoma.

    Evidence RNA immunoprecipitation, actinomycin D stability assay, gain/loss models, and in vivo assays

    PMID:36527113

    Open questions at the time
    • RNA-binding domain within SPTBN1 not mapped
    • Direct versus indirect mRNA stabilization not resolved
  12. 2022 Medium

    Defined a direct SPTBN1-PIK3R2 interaction that suppresses PI3K/AKT signaling in rheumatoid arthritis synoviocytes, broadening SPTBN1's anti-inflammatory scaffolding repertoire.

    Evidence Co-IP, PIK3R2 siRNA knockdown, and functional proliferation/migration/inflammation assays

    PMID:36444616

    Open questions at the time
    • Single Co-IP for binding without reciprocal/structural validation
    • Single-lab finding
  13. 2023 Medium

    Established SPTBN1 as a cytoplasmic anchor for PTTG1/securin, showing it physically restrains an oncogenic transcription factor from the nucleus.

    Evidence PTTG1 IP-proteomics, Co-IP, nuclear/cytoplasmic fractionation, confocal microscopy, and deletion-mutant binding-domain analysis

    PMID:38069214

    Open questions at the time
    • SPTBN1 region binding PTTG1 not mapped
    • Regulation of anchoring under signaling not defined
  14. 2023 Medium

    Linked tumor-cell SPTBN1 to the tumor microenvironment, showing it suppresses CXCL1 via p65 to limit M2 macrophage polarization.

    Evidence Nuclear/cytoplasmic fractionation, ChIP-qPCR, co-culture, and CXCL1 neutralizing antibody rescue

    PMID:37921259

    Open questions at the time
    • Mechanism by which SPTBN1 blocks p65 nuclear localization in this context not detailed
  15. 2024 Medium

    Demonstrated a structural membrane-repair role, showing SPTBN1 maintains osteocyte plasma membrane integrity under mechanical load to enable bone adaptation.

    Evidence MLO-Y4 siRNA knockdown, diamide treatment, DMP1-Cre Sptbn1 conditional KO mice, fluid shear stress PMD quantification, calcium imaging, and in vivo tibial loading

    PMID:39276238

    Open questions at the time
    • Molecular mechanism of membrane stabilization not resolved
    • Link between membrane integrity and downstream osteogenic signaling indirect
  16. 2025 Medium

    Resolved an m6A-based suppression of NF-κB, showing SPTBN1 promotes METTL14-mediated m6A methylation of TRIM37 to limit TRAF2 ubiquitination and inflammation.

    Evidence SPTBN1-METTL14 Co-IP, MeRIP-qPCR of TRIM37, TRIM37 overexpression rescue, and atherosclerosis mouse model

    PMID:40836352

    Open questions at the time
    • How SPTBN1 promotes METTL14 activity mechanistically unclear
    • Single-lab finding
  17. 2025 Medium

    Connected SPTBN1 isoform identity to function, showing APA driven by IGF2BP3/NUDT21 selects a long SPTBN1 isoform that binds CDK1 and blocks the G2/M transition versus a short oncogenic isoform.

    Evidence IGF2BP3-NUDT21 interaction and m6A site mapping, APA reporter, CDK1 Co-IP, cell-cycle analysis, and in vivo tumor assays

    PMID:40301554

    Open questions at the time
    • CDK1-binding interface on the long isoform not mapped
    • Generalizability of isoform switch beyond ovarian cancer unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • How SPTBN1's classical cytoskeletal/membrane-scaffolding architecture mechanistically integrates with its diverse signaling, RNA-binding, and m6A-promoting activities remains unresolved.
  • No unifying structural model connecting cytoskeletal scaffolding to signaling and RNA functions
  • Direct enzymatic versus adapter contributions to m6A and methylation pathways not reconstituted
  • Isoform- and tissue-specific division of labor across reported functions not systematically defined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 3 GO:0098772 molecular function regulator activity 3 GO:0003723 RNA binding 1 GO:0005198 structural molecule activity 1
Localization
GO:0005829 cytosol 2 GO:0005886 plasma membrane 1
Pathway
R-HSA-168256 Immune System 4 R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 2 R-HSA-8953854 Metabolism of RNA 2 R-HSA-1640170 Cell Cycle 1
Partners
CDK1METTL14PIK3R2PTTG1SMAD3SNCASOCS1SREBP1

Evidence

Reading pass · 17 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2015 SPTBN1 functions as an adapter protein required for Smad3/Smad4 complex formation during TGF-β signal transduction; loss of SPTBN1 in HCC cells activates Wnt signaling by downregulating the Wnt inhibitor kallistatin, leading to decreased β-catenin phosphorylation and increased β-catenin nuclear localization. siRNA knockdown in HCC cell lines, Western blot, xenograft tumor assay, kallistatin restoration rescue experiments Hepatology Medium 25307947
2013 SPTBN1 is a required host factor for HIV-1 infection in macrophages; it associates with HIV-1 Gag proteins. IL-27 inhibits HIV-1 infection by down-regulating SPTBN1 through a TAK-1-mediated MAPK signaling pathway. Knockdown of SPTBN1 strongly inhibits HIV-1 infection, while overexpression restores susceptibility in IL-27-treated macrophages. siRNA knockdown, overexpression, co-immunoprecipitation (SPTBN1 with HIV-1 Gag), IL-27 treatment with SPTBN1 modulation The Journal of experimental medicine High 23460728
2014 SPTBN1 and SMAD3 collaborate to suppress STAT3 transcription in HCC; loss of SPTBN1 or SMAD3 upregulates STAT3 promoter activity via CRE and STAT-binding elements, mediated by increased binding of ATF3 and CREB2 to the STAT3 promoter CRE site. siRNA knockdown in HCC cell lines, luciferase reporter assay, ChIP-qPCR, Western blot, colony formation assay; validated in SPTBN1+/- mouse livers Carcinogenesis Medium 25096061
2021 Loss of SPTBN1 in HCC cells increases p65 protein stability by downregulating SOCS1 (an E3 ligase of p65), leading to enhanced NF-κB activation and increased expression of pro-inflammatory cytokines IL-1α, IL-1β, and IL-6. Restoration of SOCS1 abrogates SPTBN1 loss-associated p65 elevation. siRNA knockdown, immunoprecipitation-Western blot, luciferase reporter assay, ChIP-qPCR, EMSA, ELISA, FACS; validated in Sptbn1+/- mice Theranostics High 33754058
2007 SPTBN1-FLT3 fusion protein (from t(2;13) translocation) constitutively activates FLT3 kinase activity, transforms Ba/F3 cells to growth factor independence, and constitutively phosphorylates ERK1/2; growth is inhibited by FLT3-targeted TKIs (SU11657, PKC412, TKI258) but not imatinib. Ba/F3 transformation assay, RT-PCR fusion identification, phosphorylation analysis, small-molecule inhibitor dose-response Experimental hematology Medium 17764812
2021 SPTBN1 promotes SETD7-mediated YAP methylation leading to YAP degradation and inactivation; loss of SPTBN1 reduces SETD7 expression, increases YAP stability and nuclear localization, and impairs autophagy in hepatic stem cells and HCC cells. YAP inhibition reverses the autophagy impairment caused by SPTBN1 deficiency. Sptbn1+/- mouse model with DDC treatment, rapamycin autophagy assay, YAP inhibition rescue, Western blot for SETD7/YAP Cellular and molecular gastroenterology and hepatology Medium 34737104
2021 SPTBN1 and CASPASE-3 interact in the context of a high-fat/western diet: HFD/WD induces SPTBN1 and SREBP1 cleavage by CASPASE-3, and the cleaved SPTBN1 product interacts with cleaved SREBP1 to promote expression of lipogenic genes with sterol response elements, driving steatohepatitis and liver cancer. Hepatocyte-specific knockout of SPTBN1 protects mice from HFD/WD-induced liver disease. Hepatocyte-specific SPTBN1 knockout mice, siRNA therapy in mice, biochemical analysis of CASPASE-3 cleavage, co-immunoprecipitation of SPTBN1/SREBP1 cleavage products, human NASH tissue analysis Science translational medicine High 34910547
2012 SPTBN1 directly interacts with α-synuclein via GST pull-down and co-immunoprecipitation; the two proteins colocalize in neuronal cells. SPTBN1 overexpression induces excessive neurite branching in SH-SY5Y cells, which is reversed by co-expression of α-synuclein, indicating α-synuclein modulates SPTBN1-driven neurite outgrowth. Phage display, GST pull-down, co-immunoprecipitation, co-localization, transfection/overexpression in SH-SY5Y cells Biochemical and biophysical research communications Medium 22771809
2020 SPTBN1 suppresses JAK/STAT3 signaling in epithelial ovarian cancer via upregulation of SOCS3; loss of SPTBN1 activates p-JAK2 and p-STAT3, promotes EMT (increased Vimentin, decreased E-cadherin), and enhances cell proliferation and migration. These effects were reversed by SOCS3 overexpression or JAK2 inhibition. siRNA knockdown in EOC cell lines (A2780, HO8910), SOCS3 overexpression rescue, JAK2 inhibitor treatment, mouse embryonic fibroblasts from Sptbn1 KO, xenograft in vivo model, IHC Aging Medium 32516133
2022 SPTBN1 functions as an RNA-binding protein that regulates the mRNA stability of GPT2 (glutamate pyruvate transaminase 2); loss of SPTBN1 upregulates GPT2, activating GPT2-dependent glycolysis to promote renal clear cell carcinoma progression. RNA immunoprecipitation (RIP), actinomycin D mRNA stability assay, gain/loss-of-function cell models, in vitro and in vivo assays, specific inhibitors and rescue experiments Journal of translational medicine Medium 36527113
2023 SPTBN1 anchors PTTG1 (securin) in the cytoplasm, preventing its nuclear translocation and oncogenic transcriptional activity (on MMP-2 and E-cadherin). SPTBN1 downregulation causes PTTG1 nuclear translocation and promotes invasiveness. A PTTG1 deletion mutant lacking the SPTBN1-binding domain localizes strongly to the nucleus. PTTG1 immunoprecipitation proteomics, co-immunoprecipitation, Western blot, confocal microscopy, cytoplasmic/nuclear fractionation, deletion mutant analysis, sphere-forming assay International journal of molecular sciences Medium 38069214
2022 SPTBN1 binds to PIK3R2 in fibroblast-like synoviocytes (FLSs); this interaction suppresses the PI3K/AKT signaling pathway. In SPTBN1-overexpressed RA-FLSs, PIK3R2 depletion reverses reduced MMP2, MMP9, IL-8, IL-1β, IL-6, and Bcl2 levels and increases p-PI3K and p-AKT. Co-immunoprecipitation (IP), Western blot, siRNA knockdown of PIK3R2, functional assays (proliferation, migration, invasion, apoptosis, inflammation) Immunity, inflammation and disease Medium 36444616
2021 Loss of SPTBN1 inhibits growth and promotes EMT in breast cancer via upregulation of miR-21; this miR-21 upregulation is dependent on stability and nuclear translocation of NF-κB p65. ChIP-qPCR and immunofluorescence showed SPTBN1 regulates miR-21 at the transcriptional level through p65. siRNA knockdown, ChIP-qPCR, immunofluorescence, xenograft model, Western blot, qPCR European journal of pharmacology Medium 34358482
2023 Tumor cell SPTBN1 inhibits M2 macrophage polarization and migration by suppressing CXCL1 expression via inhibition of p65 nuclear localization; CXCL1 neutralizing antibody reverses M2 polarization and migration promoted by SPTBN1-deficient tumor conditioned medium. Cytoplasmic/nuclear protein isolation, ChIP-qPCR, RT-qPCR, cell migration assays, CXCL1 neutralizing antibody rescue, co-culture experiments Journal of cellular physiology Medium 37921259
2025 SPTBN1 inhibits TRIM37 expression by promoting METTL14-mediated m6A methylation of TRIM37 mRNA; this suppresses TRIM37-driven K63-linked ubiquitination of TRAF2 and downstream NF-κB activation, thereby reducing oxidative stress and inflammation in endothelial cells. Co-immunoprecipitation (SPTBN1-METTL14), MeRIP-qPCR (m6A methylation of TRIM37), TRIM37 overexpression rescue, AS mouse model with SPTBN1 overexpression European journal of medical research Medium 40836352
2024 In osteocytes, SPTBN1 (β2-spectrin) maintains plasma membrane integrity under mechanical loading; knockdown or conditional knockout of Sptbn1 increases the number and size of plasma membrane disruptions (PMD) formed by fluid shear stress, impairs post-wounding cell survival, mildly alters calcium signaling from wounded osteocytes, and blunts bone adaptation (cortical thickening) to osteogenic tibial loading in vivo. siRNA knockdown in MLO-Y4 cells, diamide treatment, Sptbn1 conditional KO mice (DMP1-Cre), fluid shear stress assay, PMD quantification, calcium imaging, tibial loading in vivo protocol, histomorphometry Calcified tissue international Medium 39276238
2025 IGF2BP3 interacts with NUDT21 and, by recognizing an m6A-modified site in intron 32 of SPTBN1, recruits NUDT21 to promote usage of the SPTBN1 proximal polyadenylation site, generating a short SPTBN1 transcript isoform with oncogenic activity in ovarian cancer. The long SPTBN1 isoform inhibits tumor growth and metastasis by binding CDK1 and blocking the G2/M cell cycle transition. IGF2BP3-NUDT21 interaction assay, m6A site identification, APA reporter assays, CDK1 co-immunoprecipitation, cell cycle analysis, in vitro and in vivo tumor growth assays Communications biology Medium 40301554

Source papers

Stage 0 corpus · 38 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2016 Integrating GWAS and Co-expression Network Data Identifies Bone Mineral Density Genes SPTBN1 and MARK3 and an Osteoblast Functional Module. Cell systems 89 27866947
2015 βII-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin. Hepatology (Baltimore, Md.) 86 25307947
2013 IL-27 inhibits HIV-1 infection in human macrophages by down-regulating host factor SPTBN1 during monocyte to macrophage differentiation. The Journal of experimental medicine 68 23460728
2021 βII spectrin (SPTBN1): biological function and clinical potential in cancer and other diseases. International journal of biological sciences 64 33390831
2021 SPTBN1 inhibits inflammatory responses and hepatocarcinogenesis via the stabilization of SOCS1 and downregulation of p65 in hepatocellular carcinoma. Theranostics 55 33754058
2007 A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. Experimental hematology 41 17764812
2021 β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development. Science translational medicine 37 34910547
2012 α-Synuclein modulates neurite outgrowth by interacting with SPTBN1. Biochemical and biophysical research communications 34 22771809
2020 SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway. Aging 30 32516133
2016 Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy. Journal of hematology & oncology 29 27496196
2014 Transcriptional regulation of STAT3 by SPTBN1 and SMAD3 in HCC through cAMP-response element-binding proteins ATF3 and CREB2. Carcinogenesis 28 25096061
2008 Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders. Cancer genetics and cytogenetics 27 18262053
2019 SPTBN1 and cancer, which links? Journal of cellular physiology 26 31206681
2021 Loss of SPTBN1 Suppresses Autophagy Via SETD7-mediated YAP Methylation in Hepatocellular Carcinoma Initiation and Development. Cellular and molecular gastroenterology and hepatology 23 34737104
2021 Heterozygous variants in SPTBN1 cause intellectual disability and autism. American journal of medical genetics. Part A 22 33847457
2021 SPTBN1 Prevents Primary Osteoporosis by Modulating Osteoblasts Proliferation and Differentiation and Blood Vessels Formation in Bone. Frontiers in cell and developmental biology 21 33816505
2020 Gene-gene and gene-lifestyle interactions of AKAP11, KCNMA1, PUM1, SPTBN1, and EPDR1 on osteoporosis risk in middle-aged adults. Nutrition (Burbank, Los Angeles County, Calif.) 19 32619791
2021 SPTBN1 inhibits growth and epithelial-mesenchymal transition in breast cancer by downregulating miR-21. European journal of pharmacology 18 34358482
2022 SPTBN1 abrogates renal clear cell carcinoma progression via glycolysis reprogramming in a GPT2-dependent manner. Journal of translational medicine 11 36527113
2023 Tumor cell SPTBN1 inhibits M2 polarization of macrophages by suppressing CXCL1 expression. Journal of cellular physiology 9 37921259
2022 SPTBN1 attenuates rheumatoid arthritis synovial cell proliferation, invasion, migration and inflammatory response by binding to PIK3R2. Immunity, inflammation and disease 9 36444616
2022 Paracetamol perturbs neuronal arborization and disrupts the cytoskeletal proteins SPTBN1 and TUBB3 in both human and chicken in vitro models. Toxicology and applied pharmacology 8 35714712
2025 SPTBN1 overexpression ameliorates atherosclerosis by inhibiting oxidative stress and inflammation via regulating the TRIM37/TRAF2/NF-κB pathway. European journal of medical research 7 40836352
2024 Identification of bone mineral density associated genes with shared genetic architectures across multiple tissues: Functional insights for EPDR1, PKDCC, and SPTBN1. PloS one 7 38683846
2023 Clinical significance of nonerythrocytic spectrin Beta 1 (SPTBN1) in human kidney renal clear cell carcinoma and uveal melanoma: a study based on Pan-Cancer Analysis. BMC cancer 7 37013511
2025 IGF2BP3 recruits NUDT21 to regulate SPTBN1 alternative polyadenylation and drive ovarian cancer progression. Communications biology 6 40301554
2024 Osteocyte Sptbn1 Deficiency Alters Cell Survival and Mechanotransduction Following Formation of Plasma Membrane Disruptions (PMD) from Mechanical Loading. Calcified tissue international 6 39276238
2023 SPTBN1 Mediates the Cytoplasmic Constraint of PTTG1, Impairing Its Oncogenic Activity in Human Seminoma. International journal of molecular sciences 6 38069214
2024 Diverse clinical presentation of SPTBN1 variants: Complex versus primary attention-deficit/hyperactivity disorder. American journal of medical genetics. Part A 5 39162370
2023 Revealing the Organ-Specific Expression of SPTBN1 using Single-Cell RNA Sequencing Analysis. bioRxiv : the preprint server for biology 4 37333135
2023 Interleukin-27-induced HIV-resistant dendritic cells suppress reveres transcription following virus entry in an SPTBN1, autophagy, and YB-1 independent manner. PloS one 4 37910521
2024 GM1 Ameliorates Neuronal Injury in Rats after Cerebral Ischemia and Reperfusion: Potential Contribution of Effects on SPTBN1-mediated Signaling. Neuroscience 2 38810691
2023 Shared Genetic Architecture between Muscle and Bone: Identification and Functional Implications of EPDR1, PKDCC, and SPTBN1. bioRxiv : the preprint server for biology 2 37292779
2023 Interleukin-27-induced HIV-resistant dendritic cells suppress reveres transcription following virus entry in an SPTBN1, Autophagy, and YB-1 independent manner. bioRxiv : the preprint server for biology 2 37546823
2025 A Case of Infantile Epileptic Spasms Syndrome with the SPTBN1 Mutation and Review of βII-Spectrin Variants. Genes 1 40869952
2026 Clinical characterization of SPTBN1, SPTBN2, and SPTBN5 variants: A case series and systematic review. Seizure 0 41819009
2026 Clinical characterization and structural modeling of a novel de novo SPTBN1 missense variant in a Chinese child. BMC pediatrics 0 41862830
2025 Mechanistic study of miR‑369‑3p in regulating the Wnt/β‑catenin signaling pathway via targeting SPTBN1 in inflammatory response and bone destruction of rheumatoid arthritis. Molecular medicine reports 0 41416430

Missed literature

Know a paper Affinage missed for SPTBN1? Flag it for the maintainers and the community.

No submissions yet.